Drug intelligence / Profile preview

68Ga-MM-BC1

Development stage: Phase 2
Lead developer: Peking University First Hospital
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
Administration: Intravenous

Overview

68Ga-MM-BC1 is a PET imaging radiopharmaceutical developed for the diagnosis of Multiple Myeloma (MM). It consists of a peptide or nanobody targeting BCMA (B-cell maturation antigen) that has been radiolabeled with the positron-emitting isotope gallium-68. This novel molecular probe was developed through computer-aided design to overcome limitations of traditional full-length antibody probes, which suffer from delayed tumor uptake peaks and low target-to-background ratios. The physical half-life of gallium-68 is approximately 68 minutes, after which it transforms to stable zinc-68.

Targets

BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on 68Ga-MM-BC1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-MM-BC1.

Explore the full profile